Vasopressin, N-(N-Gly-Gly)-8-Lys- introduces an N-terminal diglycine extension and lysine substitution at position eight, modifying charge distribution and ring dynamics. Researchers explore altered receptor affinity, folding patterns, and oxidative susceptibility. Applications include peptide-analogue design, structure-function studies, and cyclic-peptide modeling.
CAT No: R2591
CAS No:14943-47-6
Synonyms/Alias:Vasopressin, N-(N-gly-gly)-8-lys-;14943-47-6;Triglycyl-desglycine amide lysine vasopressin;N-(N-Glycylglycyl)-8-lysine vasopressin;Vasopressin, N-(N-glycylglycyl)-8-lysine-;Vasopressin, N-(N-glycylglycyl)-8-L-lysine-;DTXSID50164267;(2S)-1-[(4R,7S,10S,13S,16S,19R)-19-[[2-[(2-aminoacetyl)amino]acetyl]amino]-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-benzyl-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]-N-[(2S)-6-amino-1-[(2-amino-2-oxoethyl)amino]-1-oxohexan-2-yl]pyrrolidine-2-carboxamide;DTXCID1086758;
1. Myotropic activity of allatostatins in tenebrionid beetles
2. High fat diet and GLP-1 drugs induce pancreatic injury in mice
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at . We will endeavor to provide highly satisfying products and services.
Creative Peptides is a trusted CDMO partner specializing in high-quality peptide synthesis, conjugation, and manufacturing under strict cGMP compliance. With advanced technology platforms and a team of experienced scientists, we deliver tailored peptide solutions to support drug discovery, clinical development, and cosmetic innovation worldwide.
From custom peptide synthesis to complex peptide-drug conjugates, we provide flexible, end-to-end services designed to accelerate timelines and ensure regulatory excellence. Our commitment to quality, reliability, and innovation has made us a preferred partner across the pharmaceutical, biotechnology, and personal care industries.